168 related articles for article (PubMed ID: 9008941)
1. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Castillo JL; Miranda CM; Araya F; Sáez D
Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
[TBL] [Abstract][Full Text] [Related]
2. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients.
de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E
J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623
[TBL] [Abstract][Full Text] [Related]
3. N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
Traversa R; Pierantozzi M; Semprini R; Loberti M; Cicardi MC; Bassi A; Stanzione P
J Neural Transm Suppl; 1995; 45():177-85. PubMed ID: 8748624
[TBL] [Abstract][Full Text] [Related]
4. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
Rossini PM; Bassetti MA; Pasqualetti P
Electroencephalogr Clin Neurophysiol; 1995 May; 96(3):236-47. PubMed ID: 7750449
[TBL] [Abstract][Full Text] [Related]
5. Somatosensory evoked potentials and dopaminergic responsiveness to apomorphine and levodopa in parkinsonian patients.
Miranda M; Castillo JL; Araya F
Behav Neurol; 1996; 9(3):149-53. PubMed ID: 24487514
[TBL] [Abstract][Full Text] [Related]
6. Pre- and postcentral cortical somatosensory evoked potentials in hemiparkinsonism.
Huttunen J; Teräväinen H
Mov Disord; 1993 Oct; 8(4):430-6. PubMed ID: 8232352
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of somatosensory evoked potentials in spasmodic torticollis.
Mazzini L; Zaccala M; Balzarini C
Mov Disord; 1994 Jul; 9(4):426-30. PubMed ID: 7969209
[TBL] [Abstract][Full Text] [Related]
8. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
[TBL] [Abstract][Full Text] [Related]
9. Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave.
Cheron G; Piette T; Thiriaux A; Jacquy J; Godaux E
Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):491-501. PubMed ID: 7527767
[TBL] [Abstract][Full Text] [Related]
10. Somatosensory, motor and special visual evoked potentials to single and double stimulation in "Parkinson's disease" an early diagnostic test?
Jörg J; Gerhard H
J Neural Transm Suppl; 1987; 25():81-8. PubMed ID: 3480940
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
Mauguière F; Broussolle E; Isnard J
Electroencephalogr Clin Neurophysiol; 1993; 88(4):243-54. PubMed ID: 7688279
[TBL] [Abstract][Full Text] [Related]
12. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
[TBL] [Abstract][Full Text] [Related]
13. N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach.
Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Cicardi MC; Stanzione P
Electroencephalogr Clin Neurophysiol Suppl; 1996; 46():193-200. PubMed ID: 9059793
[No Abstract] [Full Text] [Related]
14. Short-latency median nerve somatosensory evoked potentials in three cases of parkinsonism and dopa responsive dystonia.
Margari L; de Mari M; Lamberti P; Iliceto G; Serlenga L; Perniola T; Rossini PM; Ferrari E
Funct Neurol; 1995; 10(2):99-105. PubMed ID: 7557558
[TBL] [Abstract][Full Text] [Related]
15. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Durif F; Deffond D; Eschalier A; Tournilhac M
Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease. Clinical and electrophysiological evaluation.
Al-Bunyan MA
Saudi Med J; 2000 Jan; 21(1):72-5. PubMed ID: 11533754
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the clinical pharmacology of Parkinson's disease.
Montastruc JL
Therapie; 1991; 46(4):293-303. PubMed ID: 1683024
[TBL] [Abstract][Full Text] [Related]
18. Somatosensory evoked potentials in migraine.
de Tommaso M; Sciruicchio V; Tota P; Megna M; Guido M; Genco S; Puca F
Funct Neurol; 1997; 12(2):77-82. PubMed ID: 9238341
[TBL] [Abstract][Full Text] [Related]
19. Frontal N30 of median nerve SSEPs for evaluation of movement disorders with destructive basal ganglia deficits.
Fukuda C; Tomita Y; Maegaki Y; Kubota N
Neuropediatrics; 2003 Aug; 34(4):205-10. PubMed ID: 12973662
[TBL] [Abstract][Full Text] [Related]
20. Time course of frontal somatosensory evoked potentials. Relation to L-dopa plasma levels and motor performance in PD.
Ulivelli M; Rossi S; Pasqualetti P; Rossini PM; Ghiglieri O; Passero S; Battistini N
Neurology; 1999 Oct; 53(7):1451-7. PubMed ID: 10534250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
